US healthcare giant Johnson & Johnson (NYSE: JNJ) slipped by 2.5% in the stock market in the two hours after it reported its fourth quarter and annual financial results for 2017.
This is despite J&J exceeding Wall Street estimates with its quarterly results overall, with the revenue total of $20.2 billion above the $20.1 billion expected, according to Thomson Reuters. Adjusted earnings per share (EPS) were $0.02 higher than anticipated, at $1.74, on adjusted net income of $4.78 billion, up about 10% from a year ago.
"The passage of legislation modernizing the US tax system enables J&J to invest in innovation at higher levels"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze